CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Reports

We found 6371 result(s)

triheptanoin (Dojolvi)

Last Updated: April 15, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: triheptanoin
Indications: Dojolvi (triheptanoin) is indicated as a source of calories and fatty acids for the treatment of adult and pediatric patients with long-chain fatty acid oxidation disorders (LC-FAOD). ​

  • Brand Name: Dojolvi
  • Manufacturer: Ultragenyx Canada Inc
  • Project Number: SR0684-000
  • Project Status: Active
  • Submission Type: Initial

ofatumumab (Kesimpta)

Last Updated: March 1, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: ofatumumab
Indications: For the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease defined by clinical and imaging features.

  • Brand Name: Kesimpta
  • Manufacturer: Novartis Pharmaceuticals Canada Inc.
  • Project Number: SR0657-000
  • Project Status: Active
  • Submission Type: Initial

nintedanib (Ofev)

Last Updated: March 1, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: nintedanib
Indications: Treatment of other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype (also known as progressive fibrosing ILD)

  • Brand Name: Ofev
  • Manufacturer: Boehringer Ingelheim (Canada) Ltd.
  • Project Number: SR0654-000
  • Project Status: Active
  • Submission Type: Initial

human insulin (Entuzity KwikPen)

Last Updated: April 13, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: human insulin
Indications: ​To improve glycemic control in adults and children with diabetes mellitus requiring more than 200 units of insulin per day.

  • Brand Name: Entuzity KwikPen
  • Manufacturer: Eli Lilly Canada Inc.
  • Project Number: SR0672-000
  • Project Status: Active
  • Submission Type: Initial

satralizumab (Enspryng)

Last Updated: December 22, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: satralizumab
Indications: ENSPRYNG (satralizumab) is indicated as monotherapy or in combination with immunosuppressive therapy (IST) for the treatment of neuromyelitis optica spectrum disorders (NMOSD) in adult and adolescent patients who are anti-aquaporin 4 (AQP4) seropositive. ENSPRYNG is not intended for acute treatment of an NMOSD relapse.

  • Brand Name: Enspryng
  • Manufacturer: Hoffmann-La Roche Limited
  • Project Number: SR0663-000
  • Project Status: Active
  • Submission Type: Initial

tucatinib (Tukysa )

Last Updated: April 13, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: tucatinib
Indications: ​Tucatinib is indicated in combination with trastuzumab and capecitabine for treatment of patients with locally advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received prior treatment with trastuzumab, pertuzumab, and trastuzumab emtansine, separately or in combination.

  • Brand Name: Tukysa
  • Manufacturer: Seagen Canada Inc.
  • Project Number: PC0243-000
  • Project Status: Active
  • Submission Type: Initial

azacitidine (Onureg)

Last Updated: April 12, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: azacitidine
Indications: ​Maintenance therapy in adult patients with acute myeloid leukemia (AML) who achieved complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following induction therapy with or without consolidation treatment, and who are not eligible for hematopoietic stem cell transplantation (HSCT).

  • Brand Name: Onureg
  • Manufacturer: Celgene Inc., a Bristol-Myers Squibb Company
  • Project Number: PC0245-000
  • Project Status: Active
  • Submission Type: Initial

chlormethine hydrochloride (Ledaga)

Last Updated: December 23, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: chlormethine hydrochloride
Indications: For the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma (MF-type CTCL) in adult patients.

  • Brand Name: Ledaga
  • Manufacturer: Recordati Rare Diseases Canada Inc.
  • Project Number: PC0242-000
  • Project Status: Active
  • Submission Type: Initial

pertuzumab (Perjeta)

Last Updated: April 15, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: pertuzumab
Indications: Perjeta in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either 2 cm in diameter or node positive).

  • Brand Name: Perjeta
  • Manufacturer: Hoffmann-La Roche Limited
  • Project Number: PC0241-000
  • Project Status: Received
  • Submission Type: Initial

upadacitinib (Rinvoq)

Last Updated: April 14, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: upadacitinib
Indications: RINVOQ is indicated for the treatment of adults and adolescents 12 years and older with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy. RINVOQ can be used with or without topical corticosteroids.​

  • Brand Name: Rinvoq
  • Manufacturer: AbbVie
  • Project Number: SR0685-000
  • Project Status: Received